两种国产卡维地洛片剂降压疗效和安全性比较  

COMPARISON OF HYPOTENSIVE EFFECT AND SAFETY OF CARVEDILOL FORM TWO DOMESTIC COMPANIES

作　　者：张向阳[1] 周慧清[1] 杨松娜[1] 胡恒慧[1] 刘美贞 徐成斌[1] 蒋宝琦[1] 孙宁玲[1] 

机构地区：[1]北京医科大学人民医院心内科,北京100044

出　　处：《中国临床药理学杂志》1999年第5期336-338,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：为比较两种国产降压药物卡维地洛降压疗效与安全性 ,采用开放性的研究方法 ,比较两组患者在治疗前后的血压、心率以及生化指标的变化。结果显示两组患者在每周的血压、心率、有效率构成、生化指标以及药物不良反应发生率等均无显著性差异 (P>0.05),而各组治疗第4周后与治疗前对比则差异均极为显著(P<0.01) ,收缩压及舒张压下降幅度达14 %以上。因此 ,两家国产卡维地洛制剂安全性较好 ,具有明显的、相似的降压疗效 ,可以作为治疗轻中度高血压病的一线用药。To compare hypotensive effect and safety of carvedilol from two domestic companies,open clinical trial is needed to analyze the changes of blood pressure, heart rate , blood chemistry and incidence of side effects pre_ and post_trial between two groups of patients. The result shows extremely statistical significance in above parameters pre_ and post_trial in each group(P<0.001), but no significance between two groups(P>0.05);and the decrease of blood pressure is more than 14%. Then we make a conclusion that there is no significant difference in antihypertensive effect and safety between carvedilol tablets from the two domestic companies.

关 键 词：卡维地洛 原发性 高血压 安全性 疗效 

分 类 号：R544.105[医药卫生—心血管疾病] R972.4[医药卫生—内科学]